Cagrilintide

Cagrilintide Dragon Pharma

Cagrilintide is a synthetic analog of the natural hormone ghrelin, which is known to stimulate gastric acid secretion and appetite. It is a peptide that acts as a potent, selective, and competitive antagonist for the ghrelin receptor, specifically the growth hormone secretagogue receptor type 1a (GHS-R1a). Research into the therapeutic potential of ghrelin antagonists like cagrilintide has focused on their role in modulating gastrointestinal motility and inhibiting food intake.

According to the medical literature, cagrilintide has been studied for its effects on gastric emptying and as a potential treatment for conditions such as gastroparesis and functional dyspepsia, which are characterized by impaired gastric motility. The rationale for its use lies in the regulation of the ghrelin system, which plays a significant role in the physiological response to food intake and the regulation of gastric emptying. By blocking the action of ghrelin, cagrilintide can enhance gastric emptying and reduce symptoms associated with these gastrointestinal disorders.

References

For comprehensive information on cagrilintide, one can refer to advanced pharmacology texts such as "Goodman and Gilman's The Pharmacological Basis of Therapeutics" or review articles in reputable journals such as "Gastroenterology" or "The Journal of Clinical Investigation." These resources provide in-depth analysis of the scientific principles underlying the drug's mechanism of action, pharmacokinetics, and pharmacodynamics, as well as the latest findings from preclinical and clinical research studies.